Page 27 - Outlayer Item News Today : Breaking News, Live Updates & Top Stories | Vimarsana

RGX-314 gene therapy administered via in-office suprachoroidal injection could provide long-lasting therapy for diabetic retinopathy.Interim data from the ongoing phase 2 ALTITUDE trial showed that the treatment was well tolerated, with no cases of intraocular inflammation over 6 months. Nearly half of the patients achieved meaningful improvement in disease severity with just one injection.

The CDC’s Advisory Committee on Immunization Practices voted unanimously on Wednesday to recommend a vaccine for tick-borne encephalitis for laboratory workers and people traveling abroad to endemic areas. Two recommendations covered lab workers with a potential exposure to the virus that causes tick-borne encephalitis (TB) and people moving or traveling to an endemic area who will have

Riociguat treatment significantly improved exercise capacity and prevented clinical worsening in patients with sarcoidosis-associated pulmonary hypertension, according to study results published in Chest.“To date, no placebo-controlled trial has evaluated treatment of sarcoidosis-associated pulmonary hypertension using time to clinical worsening as either a primary or a secondary

The FDA approved an expanded indication for the SGLT2 inhibitor empagliflozin to reduce the risk for CV death and HF hospitalization in adults with HF with reduced or preserved ejection fraction, according to an agency press release.Empagliflozin (Jardiance, Boehringer Ingelheim) was originally approved 2014 to improve glucose response for adults with type 2 diabetes. In August, the FDA approved

Agomelatine proved safe and effective in treating adolescents with major depressive disorder who received psychosocial counseling, according to a double-blind randomized controlled phase 3 trial published in Lancet Psychiatry.“Established recommendations and guidelines for treatment of moderate to severe depression in children and adolescents recommend initial treatment with